According to the Centers for Disease Control and Prevention (CDC), up to 4 million infections per year are acquired by patients in
Hospital-acquired infections impact one in every 10 patients in the
The Tavistock investment allows us to introduce the Iapyx Medical brand into the marketplace in a meaningful way, and aggressively build on the companys longstanding success designing innovative medical devices, said Joel Smith, president and CEO of Iapyx Medical. This funding gives us an increased ability to develop and market products that will set the standard for hospital care.
The company has re-named itself after Iapyx, a wound healer and battlefield surgeon in Greek mythology who is one of the first people credited with identifying and treating the problem of surgical site infections.
Iapyx Medical develops and manufactures single-use medical devices designed to combat the epidemic of hospital-acquired infections. Today, Iapyx markets two product families that protect both patients and clinicians. The Iso-Line family uses isolation techniques to prevent exposure of patients and clinicians to contaminated devices. The Stable-Line® family of catheter stabilization devices is designed to minimize the risk of site infections, bloodstream and urinary tract infections and other catheter-related complications.
Source: Iapyx Medical